Truvada vs Descovy: Key Differences and How Doctors Tell Them Apart

Truvada and Descovy are once-daily prescription medicines used for HIV pre-exposure prophylaxis (PrEP), which reduces the chance of acquiring HIV when taken as prescribed. The main practical difference is that Truvada is approved for HIV prevention through sex and injection drug use, whereas Descovy is not approved for people at risk through receptive vaginal sex.

Truvada vs Descovy at a Glance

Feature	Truvada	Descovy
Active medicines	Emtricitabine plus tenofovir disoproxil fumarate (TDF)	Emtricitabine plus tenofovir alafenamide (TAF)
PrEP use	Prevents HIV from sexual exposure and injection drug use when used as prescribed	Prevents HIV from sexual exposure when used as prescribed, except receptive vaginal sex
Kidney and bone considerations	May have greater effects on kidney function markers and bone mineral density in some people	Usually produces lower blood levels of tenofovir and may be preferred for some people with kidney or bone concerns
Weight and lipids	May have a more neutral effect on weight and blood lipids for some people	May be associated with increases in weight or cholesterol measurements in some people
Hepatitis B activity	Active against hepatitis B virus	Active against hepatitis B virus

In the comparison of truvada vs descovy, both medicines are daily oral PrEP options containing two antiviral drugs. PrEP is intended for people who do not have HIV and who may have an ongoing or occasional chance of exposure. When taken consistently, it is a highly effective part of an HIV prevention plan.

The best option is not automatically the newest medicine or the one that seems most convenient. A clinician matches the prescription to the type of possible HIV exposure, test results, kidney and bone health, other medicines, and the person’s ability to attend follow-up appointments. Condoms can still provide important protection from other sexually transmitted infections (STIs) and pregnancy.

What Truvada and Descovy Are Used For

Truvada and Descovy are brand names for combinations of antiretroviral medicines. For PrEP, they are taken by people who are HIV-negative before a potential exposure, rather than as treatment for HIV infection. They work by preventing HIV from establishing infection in the body if exposure occurs.

Truvada is approved for PrEP for adults and adolescents at risk of HIV through sex or through injection drug use. It is also approved for people whose possible sexual exposure includes receptive vaginal sex. Descovy is approved for PrEP for adults and adolescents at risk through sexual exposure, but it has not been studied and is not approved for people at risk of HIV from receptive vaginal sex.

These medicines should not be used alone to treat HIV. If a person has HIV or acquires HIV while taking PrEP, they need a complete HIV treatment regimen prescribed by an experienced clinician. HIV care commonly includes ongoing assessment of infection, immune health, and treatment response.

How a Clinician Tells Them Apart

The first and most important question is the route of potential HIV exposure. For a person who may be exposed through receptive vaginal sex, Truvada is an approved daily oral PrEP choice, while Descovy is not. For a person whose risk is through anal sex, either medication may be considered if there are no other reasons to avoid it. Truvada may also be considered when HIV exposure could occur through injection drug use.

Next, the clinician reviews kidney function. Both medicines require kidney monitoring, but the form of tenofovir in Descovy generally results in lower tenofovir levels in the bloodstream than the form in Truvada. Descovy may therefore be a suitable option for some people with reduced kidney function or factors that raise concern about kidney health. The choice still depends on the individual test results and the approved use of the medicine.

Bone health can also matter. Truvada can cause small reductions in bone mineral density in some users, particularly early in use, although serious bone problems are uncommon. A clinician may weigh this issue more carefully in people with osteoporosis, a history of fractures, very low body weight, certain hormonal conditions, or medicines that can affect bones.

Finally, clinicians discuss metabolic health and preferences. Some people taking Descovy have experienced increases in body weight or lipid measurements, so a clinician may monitor weight and cholesterol where appropriate. This does not mean Descovy is unsuitable for everyone; it means the selection should reflect the whole health picture rather than one factor alone.

Tests Needed Before and During PrEP

Before prescribing either medicine, a clinician confirms that the person does not have HIV. This step is essential because taking only two drugs when HIV is already present can allow drug resistance to develop. Testing may include an HIV antigen/antibody test and, when recent exposure or possible early HIV symptoms are present, an HIV RNA test.

Initial assessment also usually includes kidney function testing, hepatitis B testing, and screening for other STIs. Pregnancy testing may be appropriate for some people. A clinician also asks about current medicines, supplements, and medical conditions, because some drugs can affect kidney function or require closer monitoring.

Follow-up visits and laboratory tests are part of safe PrEP care. HIV testing is generally repeated regularly while PrEP is used, and kidney testing is repeated according to the medicine chosen and the person’s age, results, and health history. STI screening, adherence support, condom counseling, and discussion of changing risk circumstances are also important parts of preventive care.

What to Do in Common Situations

A person considering PrEP because of receptive vaginal sex should discuss Truvada or another PrEP option approved for that exposure with a qualified clinician. Descovy should not be substituted in this situation simply because it may have different kidney or bone effects. The protection offered by a PrEP medicine must match the person’s actual route of exposure.

Someone with possible kidney disease, declining kidney test results, or significant bone-health concerns should not stop or switch PrEP without medical advice. A clinician can review whether Descovy, Truvada, or a non-oral PrEP option may be appropriate, while considering the person’s type of exposure and full medical history.

People who inject drugs and may share needles or other injection equipment should seek individualized prevention advice. Truvada is approved for PrEP in this setting, but PrEP works best alongside access to sterile injection equipment, testing, vaccination where indicated, and support for substance use if wanted.

If a person misses doses, they should avoid doubling up unless specifically instructed by their prescriber. Taking medication consistently is important, but occasional missed doses can be discussed without judgment at a follow-up visit. A clinician can help identify reminders or a prevention plan that better fits daily life.

Safety, Side Effects, and Hepatitis B

Both medicines are generally well tolerated. Some people may notice nausea, headache, tiredness, abdominal discomfort, or diarrhea when starting PrEP; these effects are often mild and improve over time. Persistent, severe, or troubling symptoms should be discussed with the prescribing clinician rather than managed by stopping medication independently.

Although kidney problems are uncommon, both medicines can affect kidney function in some people. The risk may be higher in those with existing kidney disease or those taking medicines that can strain the kidneys. Regular blood tests help the care team recognize changes early and adjust the plan if needed.

Both Truvada and Descovy are active against hepatitis B virus (HBV). A person with chronic hepatitis B may experience a flare of hepatitis if either medicine is stopped suddenly, because HBV can become more active after treatment is withdrawn. Hepatitis B testing before PrEP and planned follow-up if PrEP is stopped are therefore especially important.

Neither Truvada nor Descovy prevents every STI. Condoms, testing, vaccination for infections such as hepatitis A and hepatitis B when appropriate, and prompt assessment of symptoms all remain useful. PrEP also does not prevent pregnancy, so contraception can be discussed when needed.

When to Seek Medical Care

Medical advice should be sought promptly after a possible HIV exposure if a person is not taking PrEP, has missed enough doses to be concerned about protection, or believes a condom may have failed. Post-exposure prophylaxis (PEP) may be an option when started as soon as possible after a potential exposure and no later than 72 hours. Urgent evaluation is important because this treatment window is short.

A person taking PrEP should contact a clinician promptly if they develop symptoms that could suggest early HIV infection, especially after a recent exposure. These may include fever, rash, sore throat, swollen lymph nodes, marked tiredness, muscle aches, or mouth ulcers. These symptoms are common in many illnesses and do not confirm HIV, but they should be assessed before continuing or restarting PrEP.

New yellowing of the skin or eyes, dark urine, severe abdominal pain, markedly reduced urination, swelling, or an allergic reaction also needs timely medical assessment. Anyone with a new STI diagnosis, pregnancy, a new medication, or a change in kidney health should inform their PrEP clinician so the prevention plan can be reviewed safely.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals can assess HIV prevention needs, arrange appropriate testing, and support international patients with individualized PrEP care.

Frequently asked questions

Is Descovy better than Truvada for PrEP?

Neither medicine is universally better. Descovy may be preferable for some people with kidney or bone-health concerns, while Truvada is the approved oral PrEP option for receptive vaginal sex and for injection drug use. A clinician can help choose based on the person's exposures, test results, and overall health.

Can Descovy be used for vaginal sex?

Descovy is not approved for PrEP for people at risk of HIV through receptive vaginal sex. This is because its effectiveness for that exposure has not been established in clinical studies. People with this type of possible exposure should discuss approved alternatives with a clinician.

Do Truvada and Descovy work immediately?

PrEP does not provide maximum protection immediately after the first tablet. The time needed to reach protective drug levels varies by the type of exposure and the medicine prescribed. A healthcare professional can explain when to start relying on a specific PrEP regimen and what protection to use in the meantime.

Can a person switch from Truvada to Descovy?

Many people can switch, but the change should be made with a prescriber. The clinician will confirm that Descovy is appropriate for the person's route of exposure and review HIV status, kidney function, hepatitis B status, and other relevant factors. It is important not to have gaps in protection during a planned change.

Do Truvada and Descovy cause side effects?

Some people have mild short-term effects such as nausea, headache, tiredness, or stomach upset. Truvada may affect kidney markers and bone density in some users, while Descovy may affect weight or lipid levels in some people. Regular follow-up helps identify and manage concerns early.

Can PrEP be stopped when HIV risk changes?

PrEP can be stopped or restarted when circumstances change, but this should be planned with a clinician. HIV testing is needed before restarting, and people with hepatitis B need particular guidance because stopping either medicine can trigger hepatitis B activity. Another prevention method may be needed during any transition.

References

• Centers for Disease Control and Prevention
• U.S. Food and Drug Administration
• World Health Organization
• National Institutes of Health
• European AIDS Clinical Society

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.